Marker Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Marker Therapeutics

14/05/2022 13:38

* Marker Therapeutics Inc  MRKR.OQ  reported a quarterly
adjusted
loss of 12 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 13 cents per share.
    * Revenue was $964.00 thousand​;  analysts expected zero. 
    * Marker Therapeutics Inc's reported EPS for the quarter was
a
loss of 12 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Marker Therapeutics Inc shares had fallen by 25.1% this
quarter and lost 65.3% so far this year.
    * The company reported a quarterly loss of $9.91 million.
    * Wall Street's median 12-month price target for Marker
Therapeutics Inc is $4.25 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 14 at 12:38 p.m.  ​All
figures in US dollars unless otherwise stated